论文部分内容阅读
Background Lung cancer is a severe disease and is the leading cause of death from cancer.Lung cancer can be classified as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) while NSCLC dominates over 90 ％ of all lung cancer cases.Epidermal growth factor receptor (EGFR) mutations are common in NSCLC.Gefitinib is a tyrosine kinase inhibitor (TKI) for inhibiting EGFR, which interrupts EGFR downstream anti-apoptotic signaling.However, in clinic, after 6～8 months treatment, patients with EGFR additional T790M mutation frequently show resistance to gefitinib.